NBIX vs. BMY
Compare and contrast key facts about Neurocrine Biosciences, Inc. (NBIX) and Bristol-Myers Squibb Company (BMY).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: NBIX or BMY.
Correlation
The correlation between NBIX and BMY is 0.46, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.
Performance
NBIX vs. BMY - Performance Comparison
Loading data...
Key characteristics
NBIX:
-0.35
BMY:
0.59
NBIX:
-0.19
BMY:
1.00
NBIX:
0.97
BMY:
1.12
NBIX:
-0.34
BMY:
0.34
NBIX:
-0.74
BMY:
1.82
NBIX:
19.50%
BMY:
8.95%
NBIX:
41.85%
BMY:
31.46%
NBIX:
-97.21%
BMY:
-70.62%
NBIX:
-21.60%
BMY:
-35.79%
Fundamentals
NBIX:
$11.79B
BMY:
$95.34B
NBIX:
$2.95
BMY:
$2.68
NBIX:
40.38
BMY:
17.48
NBIX:
0.27
BMY:
2.26
NBIX:
4.89
BMY:
2.00
NBIX:
4.71
BMY:
5.50
NBIX:
$2.41B
BMY:
$47.64B
NBIX:
$2.37B
BMY:
$31.43B
NBIX:
$539.80M
BMY:
$16.18B
Returns By Period
In the year-to-date period, NBIX achieves a -11.96% return, which is significantly higher than BMY's -15.35% return. Over the past 10 years, NBIX has outperformed BMY with an annualized return of 11.01%, while BMY has yielded a comparatively lower -0.44% annualized return.
NBIX
-11.96%
16.43%
-4.35%
-14.47%
12.41%
-0.75%
11.01%
BMY
-15.35%
-3.46%
-18.67%
18.33%
-11.84%
-1.54%
-0.44%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
NBIX vs. BMY — Risk-Adjusted Performance Rank
NBIX
BMY
NBIX vs. BMY - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Neurocrine Biosciences, Inc. (NBIX) and Bristol-Myers Squibb Company (BMY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Loading data...
Dividends
NBIX vs. BMY - Dividend Comparison
NBIX has not paid dividends to shareholders, while BMY's dividend yield for the trailing twelve months is around 5.21%.
| TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
NBIX Neurocrine Biosciences, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
BMY Bristol-Myers Squibb Company | 5.21% | 4.24% | 4.44% | 3.00% | 2.36% | 3.69% | 2.55% | 3.08% | 2.55% | 1.95% | 2.17% | 2.46% |
Drawdowns
NBIX vs. BMY - Drawdown Comparison
The maximum NBIX drawdown since its inception was -97.21%, which is greater than BMY's maximum drawdown of -70.62%. Use the drawdown chart below to compare losses from any high point for NBIX and BMY. For additional features, visit the drawdowns tool.
Loading data...
Volatility
NBIX vs. BMY - Volatility Comparison
Neurocrine Biosciences, Inc. (NBIX) and Bristol-Myers Squibb Company (BMY) have volatilities of 11.43% and 11.41%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.
Loading data...
Financials
NBIX vs. BMY - Financials Comparison
This section allows you to compare key financial metrics between Neurocrine Biosciences, Inc. and Bristol-Myers Squibb Company. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
NBIX vs. BMY - Profitability Comparison
NBIX - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Neurocrine Biosciences, Inc. reported a gross profit of 563.40M and revenue of 572.60M. Therefore, the gross margin over that period was 98.4%.
BMY - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Bristol-Myers Squibb Company reported a gross profit of 8.17B and revenue of 11.20B. Therefore, the gross margin over that period was 72.9%.
NBIX - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Neurocrine Biosciences, Inc. reported an operating income of 23.60M and revenue of 572.60M, resulting in an operating margin of 4.1%.
BMY - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Bristol-Myers Squibb Company reported an operating income of 3.52B and revenue of 11.20B, resulting in an operating margin of 31.4%.
NBIX - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Neurocrine Biosciences, Inc. reported a net income of 7.90M and revenue of 572.60M, resulting in a net margin of 1.4%.
BMY - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Bristol-Myers Squibb Company reported a net income of 2.46B and revenue of 11.20B, resulting in a net margin of 21.9%.